Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Patient Officer | February 15, 2019 | March 06, 2019 |
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | June 25, 2024 | June 27, 2024 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
GILEAD SCIENCES, INC.
Report date February 15, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,046 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 330 · Balance 58,046 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.01 · Expires 2029-03-01 | Direct | 9,640 |
Reported balance
After 2019-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-01 · Grant · Acquired 9,640 · Balance 9,640 F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,530 |
Reported balance
After 2019-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-01 · Grant · Acquired 1,890 · Balance 15,530 F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
Lunai Bioworks Inc.
Report date June 25, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2034-06-25 | Direct | 48,137 |
Reported balance
After 2024-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-25 · Grant · Acquired 48,137 · Balance 48,137 |
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,685 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 47,685 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2018 Filed Mar 6, 2018 00:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,099 | $79.41 | $246,096.55 |
DisclosureSEC source: 0001127602-18-010234 · form4.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,426 F5 · price: Sale prices reported for the transactions reported here range from $79.22 to $79.66. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,200 | $78.92 | $1,278,575.28 |
DisclosureSEC source: 0001127602-18-010234 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,525 F4 · price: Sale prices reported for the transactions reported here range from $78.21 to $79.21. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,701 | $77.64 | $442,642.74 |
DisclosureSEC source: 0001127602-18-010234 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,725 F3 · price: Sale prices reported for the transactions reported here range from $77.17 to $78.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 17,250 | $40.56 | $699,660.00 |
DisclosureSEC source: 0001127602-18-010234 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 21, 2018 Filed Feb 24, 2018 00:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 5,894 | $80.69 | $475,586.86 |
DisclosureSEC source: 0001127602-18-008148 · form4.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,176 Read SEC document |
| February 21, 2018 Filed Feb 24, 2018 00:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 5,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008148 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,070 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 21, 2018 Filed Feb 24, 2018 00:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 14,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008148 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,398 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 23:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 14,435 | $81.54 | $1,176,992.37 |
DisclosureSEC source: 0001127602-18-007629 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Open Market Sale of Family Trust Shares F2 · price: Sale prices reported for the transactions reported here range from $81.4601 to $81.60. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 15, 2018 Filed Feb 24, 2018 00:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 340 | $62.35 | $21,198.15 |
DisclosureSEC source: 0001127602-18-008148 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,078 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 62,910 | $0.00 Strike: $83.49 | $0.00 |
DisclosureSEC source: 0001127602-18-004188 · form4.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,910 Underlying: Common Stock · 62,910 shares Expires 2028-02-01 F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 17,250 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-18-004188 · form4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,846 Underlying: Common Stock · 17,250 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,214 | $83.66 | $1,272,804.76 |
DisclosureSEC source: 0001127602-18-004188 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,738 F4 · price: Sale prices reported for the transactions reported here range from $83.49 to $84.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,786 | $83.29 | $815,055.39 |
DisclosureSEC source: 0001127602-18-004188 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,952 F3 · price: Sale prices reported for the transactions reported here range from $82.49 to $83.49. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 17,250 | $40.56 | $699,660.00 |
DisclosureSEC source: 0001127602-18-004188 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 22:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 18,374 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-18-001879 · form4.xml · derivative · entry 7 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,096 Underlying: Common Stock · 18,374 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 22:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,501 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-18-001879 · form4.xml · derivative · entry 6 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,501 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 22:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,125 | $79.00 | $325,875.00 |
DisclosureSEC source: 0001127602-18-001879 · form4.xml · nonDerivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,488 Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 22:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 18,374 | $79.00 | $1,451,546.00 |
DisclosureSEC source: 0001127602-18-001879 · form4.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,613 Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 22:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,501 | $79.00 | $592,579.00 |
DisclosureSEC source: 0001127602-18-001879 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,987 Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 22:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 18,374 | $40.56 | $745,249.44 |
DisclosureSEC source: 0001127602-18-001879 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 22:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,501 | $24.91 | $186,812.41 |
DisclosureSEC source: 0001127602-18-001879 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-18-001218 · form4.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Underlying: Common Stock · 8,625 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,675 | $73.86 | $419,133.37 |
DisclosureSEC source: 0001127602-18-001218 · form4.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,613 F4 · price: Sale prices reported for the transactions reported here range from $73.37 to $74.24. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 700 | $72.34 | $50,635.97 |
DisclosureSEC source: 0001127602-18-001218 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,288 F3 · price: Sale prices reported for the transactions reported here range from $71.88 to $72.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,625 | $74.00 | $638,250.00 |
DisclosureSEC source: 0001127602-18-001218 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,988 Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,625 | $24.91 | $214,805.63 |
DisclosureSEC source: 0001127602-18-001218 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 23:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-17-033980 · form4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,126 Underlying: Common Stock · 8,625 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 23:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,600 | $75.20 | $270,715.68 |
DisclosureSEC source: 0001127602-17-033980 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,988 F3 · price: Sale prices reported for the transaction reported here range from $74.88 to $75.57. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 23:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,400 | $74.46 | $848,836.02 |
DisclosureSEC source: 0001127602-17-033980 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,588 F2 · price: Sale prices reported for the transaction reported here range from $73.86 to $74.82. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 23:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,625 | $24.91 | $214,805.63 |
DisclosureSEC source: 0001127602-17-033980 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-17-031273 · form4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,751 Underlying: Common Stock · 8,625 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,600 | $75.48 | $120,772.96 |
DisclosureSEC source: 0001127602-17-031273 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,363 F4 · price: Sale prices reported for the transactions reported here range from $75.25 to $75.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 13,400 | $74.74 | $1,001,511.98 |
DisclosureSEC source: 0001127602-17-031273 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,963 F3 · price: Sale prices reported for the transactions reported here range from $74.22 to $75.21. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,625 | $24.91 | $214,805.63 |
DisclosureSEC source: 0001127602-17-031273 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 17,250 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-17-029287 · form4.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,376 Underlying: Common Stock · 17,250 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,141 | $83.52 | $178,818.68 |
DisclosureSEC source: 0001127602-17-029287 · form4.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,738 F5 · price: Sale prices reported for the transactions reported here range from $83.315 to $83.62. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 19,938 | $82.68 | $1,648,431.97 |
DisclosureSEC source: 0001127602-17-029287 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,879 F4 · price: Sale prices reported for the transactions reported here range from $82.31 to $83.26. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,921 | $81.84 | $239,056.39 |
DisclosureSEC source: 0001127602-17-029287 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,817 F3 · price: Sale prices reported for the transactions reported here range from $81.28 to $82.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 17,250 | $24.91 | $429,611.25 |
DisclosureSEC source: 0001127602-17-029287 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 17,250 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-17-027101 · form4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,626 Underlying: Common Stock · 17,250 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,737 | $83.54 | $312,207.29 |
DisclosureSEC source: 0001127602-17-027101 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,488 F4 · price: Sale prices reported for the transactions reported here range from $83.32 to $84.05. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 21,263 | $82.96 | $1,763,980.61 |
DisclosureSEC source: 0001127602-17-027101 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,225 F3 · price: Sale prices reported for the transactions reported here range from $82.31 to $83.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 17,250 | $24.91 | $429,611.25 |
DisclosureSEC source: 0001127602-17-027101 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 21,001 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001127602-17-026845 · form4.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,001 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 22,124 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-17-026845 · form4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,876 Underlying: Common Stock · 22,124 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 50,000 | $79.00 | $3,950,000.00 |
DisclosureSEC source: 0001127602-17-026845 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,238 Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 21,001 | $26.99 | $566,816.99 |
DisclosureSEC source: 0001127602-17-026845 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 22,124 | $24.91 | $550,998.22 |
DisclosureSEC source: 0001127602-17-026845 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 22:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001127602-17-024923 · form4.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,001 Underlying: Common Stock · 8,625 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 22:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,000 | $75.88 | $1,138,189.50 |
DisclosureSEC source: 0001127602-17-024923 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,113 F3 · price: Sale prices reported for the transactions reported here range from $75.61 to $76.32. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.